Cancer treatment is not just a medical challenge; it is also a major financial burden for millions of families. The high cost of medicines often forces patients to compromise on treatment, making affordability an essential part of healthcare policy. The Government’s decision to cap trade margins on 137 non scheduled anti cancer medicines at 30 per cent is therefore a significant step towards making cancer care more accessible.
Announced by the National Pharmaceutical Pricing Authority (NPPA) on October 17, 2026, the revised prices will come into effect from November 9. The move is expected to reduce medicine prices by an average of 20 to 70 per cent, with the highest reported reduction reaching 96.45 per cent. Estimated savings for patients stand at ₹3,357.49 crore. By November 4, 70 companies had submitted revised prices covering 120 medicines.
The decision addresses a long standing concern over excessive markups between manufacturers, distributors and retail pharmacies. By limiting trade margins, the government has attempted to ensure that patients are not burdened with unnecessarily inflated medicine prices. This is particularly important for cancer patients, many of whom require prolonged treatment and expensive medicines.
However, affordable medicines are only one part of the larger healthcare challenge. Timely diagnosis, access to specialists, hospital infrastructure and continuity of treatment are equally important. Programmes such as Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, which provides health coverage of ₹5 lakh per family annually to eligible beneficiaries, have helped expand access to hospital care. Under the scheme, 19.5 lakh medical oncology admissions worth approximately ₹2,926 crore had been authorised by November 4, 2026.
Preventive healthcare also deserves equal attention. More than 1.86 lakh Ayushman Arogya Mandirs are providing screening for common cancers, including oral, breast and cervical cancer. The nationwide HPV vaccination campaign, launched in February 2026 for eligible 14 year old girls, has administered more than 80 lakh free vaccine doses as of September 11, 2026.
Affordable medicine initiatives such as Jan Aushadhi and AMRIT further strengthen access to essential drugs. With 20,149 Jan Aushadhi Kendras across the country and 285 AMRIT outlets operating in 24 States and four Union Territories, these programmes are helping reduce out of pocket healthcare expenditure.
Yet, the real test of these initiatives lies in their implementation. Revised prices must be displayed transparently, hospitals and pharmacies must comply with the new limits, and patients must be able to verify medicine prices without difficulty. Equally important is ensuring that price regulation does not affect the availability of essential cancer medicines.
Making cancer treatment affordable requires a comprehensive approach that combines price regulation, early detection, accessible hospitals and reliable medicine supplies. The latest decision is a welcome step, but its success will ultimately be measured by how many families can continue treatment without facing financial distress. Healthcare must not become a privilege determined by income. Access to timely and affordable cancer treatment should remain a fundamental priority of public policy.
